Pregnancy outcomes and postpartum relapse rates in women with RRMS treated with alemtuzumab in the phase 2 and 3 clinical development program over 16 years

CAMMS223, CARE-MS I, CARE-MS II, CAMMS03409, and TOPAZ Investigators

Research output: Contribution to journalArticlepeer-review

Fingerprint Dive into the research topics of 'Pregnancy outcomes and postpartum relapse rates in women with RRMS treated with alemtuzumab in the phase 2 and 3 clinical development program over 16 years'. Together they form a unique fingerprint.

Medicine & Life Sciences